PMID- 26937231
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160303
LR  - 20220409
IS  - 1598-2629 (Print)
IS  - 2092-6685 (Electronic)
IS  - 1598-2629 (Linking)
VI  - 16
IP  - 1
DP  - 2016 Feb
TI  - Dendritic Cell-based Immunotherapy for Rheumatoid Arthritis: from Bench to 
      Bedside.
PG  - 44-51
LID - 10.4110/in.2016.16.1.44 [doi]
AB  - Dendritic cells (DCs) are professional antigen presenting cells, and play an 
      important role in the induction of antigen-specific adaptive immunity. However, 
      some DC populations are involved in immune regulation and immune tolerance. These 
      DC populations are believed to take part in the control of immune exaggeration 
      and immune disorder, and maintain immune homeostasis in the body. Tolerogenic DCs 
      (tolDCs) can be generated in vitro by genetic or pharmacological modification or 
      by controlling the maturation stages of cytokine-derived DCs. These tolDCs have 
      been investigated for the treatment of rheumatoid arthritis (RA) in experimental 
      animal models. In the last decade, several in vitro and in vivo approaches have 
      been translated into clinical trials. As of 2015, three tolDC trials for RA are 
      on the list of ClinicalTrial.gov (www.clinicaltrials.gov). Other trials for RA 
      are in progress and will be listed soon. In this review, we discuss the evolution 
      of tolDC-based immunotherapy for RA and its limitations and future prospects.
FAU - Ahmed, Md Selim
AU  - Ahmed MS
AD  - Department of Biological Science, Sungkyunkwan University, Suwon 16419, Korea.
FAU - Bae, Yong-Soo
AU  - Bae YS
AD  - Department of Biological Science, Sungkyunkwan University, Suwon 16419, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160225
PL  - Korea (South)
TA  - Immune Netw
JT  - Immune network
JID - 101137270
PMC - PMC4770099
OTO - NOTNLM
OT  - Clinical study
OT  - Future
OT  - Immunotherapy
OT  - Limitation
OT  - Mouse collagen-induced arthritis (CIA)
OT  - Rheumatoid arthritis (RA)
OT  - Tolerance
OT  - Tolerogenic dendritic cell (tolDC)
OT  - Treg
COIS- CONFLICTS OF INTEREST: The authors have no financial conflict of interest.
EDAT- 2016/03/05 06:00
MHDA- 2016/03/05 06:01
PMCR- 2016/02/01
CRDT- 2016/03/04 06:00
PHST- 2015/12/21 00:00 [received]
PHST- 2016/01/30 00:00 [revised]
PHST- 2016/02/02 00:00 [accepted]
PHST- 2016/03/04 06:00 [entrez]
PHST- 2016/03/05 06:00 [pubmed]
PHST- 2016/03/05 06:01 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - 10.4110/in.2016.16.1.44 [doi]
PST - ppublish
SO  - Immune Netw. 2016 Feb;16(1):44-51. doi: 10.4110/in.2016.16.1.44. Epub 2016 Feb 
      25.